Introduction: Anti-vascular endothelial growth factor (VEGF) therapy has become the most
commonly used treatment for macular edema secondary to retinal vein occlusion (RVO) …

Background Macular oedema secondary to retinal vein occlusion (RVO) can cause vision
loss due to blockage of the central retinal vein (CRVO) or a branch retinal vein (BRVO). This …

Purpose To evaluate the available evidence on the ocular safety and efficacy of current
therapeutic alternatives for the management of macular edema (ME) secondary to branch …

Purpose To evaluate the outcomes of different intravitreal injections for the treatment of
retinal vein occlusion including central retinal vein occlusion (CRVO) and branch retinal vein …

Objective To compare the efficacy and safety of approved treatments for macular oedema
secondary to branch retinal vein occlusion (BRVO). Design Randomised controlled trials …

Background Branch retinal vein occlusion (BRVO) is one of the most commonly occurring
retinal vascular abnormalities. The most common cause of visual loss in people with BRVO …

Objectives To assess the safety of intravitreal bevacizumab (IVB) as a monotherapy and to
evaluate the relationship between quality of treatment and adverse events. Data sources …

Introduction This systematic review assesses the effectiveness of intravitreal bevacizumab
(IVB) versus a comparison group in the treatment of branch retinal vein occlusion (BRVO) …

Background Vascular endothelial growth factor inhibitors (VEGFis) have transformed the
treatment of many retinal diseases, including diabetic maculopathy. Increasing evidence …

Purpose The objective of his study was to compare the visual and anatomical outcomes in
treatment-naïve patients with macular edema secondary to retinal vein occlusion after …